CRD 3874
Alternative Names: CRD-3874; CRD3874-SILatest Information Update: 22 Jun 2024
At a glance
- Originator Curadev Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Merkel cell carcinoma; Sarcoma
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 15 Feb 2024 Curadev Pharma receives approval from the US FDA for use of CRD 3874 in first-in-human studies in patients with advanced solid cancers
- 15 Feb 2024 Adverse events and pharmacodynamics data from preclinical studies released by Curadev Pharma